Background: The aim of this study was to investigate the molecular characteristics of each subtype of the EML4-ALK fusion gene and to evaluate the efficacy of first-line crizotinib or pemetrexed in combination with platinum in the treatment of patients with advanced NSL4-ALK fusion subtypes of advanced NSCLC. Conclusion: Among all ALK fusion subtypes, E13:A20 subtype (V1 variants) is the most common. Smoking history was a factor affecting crizotinib PFS. Compared with chemotherapy, patients with E20:A20 subtype (V2 variant) showed significant benefit with crizotinib. The median PFS of the pemetrexed combined with platinum regimen was lower than that of the E13:A20 subtype. READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/j.jtho.2019.08.1830
Authors: H. Wang, H. Li, J. Ma, X. Yan, P. Li, M. Zhang, X. Zhang, G. Zhang, Z. Ma
